[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368920-105":59,"doc-detail-368920-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","egfr-blockade-confers-sensitivity-to-pan-ras-inhibitors-in-kras-mutated-cancers-research-abstract","EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers - Research Abstract","","KRAS is a frequently mutated oncogene in human cancers, yet KRAS G12C/G12D inhibitors do not benefit patients with other hotspot KRAS mutations. This study investigates whether resistance to pan-RAS inhibition can be overcome by targeting EGFR. Using CRISPR/Cas9 sgRNA screening, EGFR is identified as correlating with sensitivity to the pan-RAS inhibitor RMC-7977. Genetic or pharmacological EGFR inhibition enhances pan-RAS inhibitor efficacy in KRAS-mutated cell lines by dampening RTK-RAS-RAF-MEK-ERK signaling and improves in vivo tumor responses in a syngeneic mouse model.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/egfr-blockade-confers-sensitivity-to-pan-ras-inhibitors-in-kras-mutated-cancers-research-abstract/368920/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/egfr-blockade-confers-sensitivity-to-pan-ras-inhibitors-in-kras-mutated-cancers-research-abstract/368920.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the key discovery regarding EGFR and pan-RAS inhibitors?","Question",{"text":112,"@type":113},"CRISPR/Cas9 sgRNA screening identified EGFR as correlating with sensitivity of KRAS-mutated tumors to the pan-RAS inhibitor RMC-7977.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does EGFR inhibition affect pan-RAS inhibitor activity in KRAS-mutated cancers?",{"text":117,"@type":113},"EGFR loss or pharmacological EGFR inhibition significantly enhances pan-RAS inhibitor effectiveness across multiple KRAS G12C or G12D cancer cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism and in vivo evidence support the combination strategy?",{"text":121,"@type":113},"Co-inhibition of EGFR and pan-RAS further reduces RTK-RAS-RAF-MEK-ERK pathway activation, and the combination shows greater therapeutic efficacy than single agents in a LL/2 syngeneic mouse tumor model.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368920,1790197875,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Cellular Oncology (2025) 48:1317–1335  \n[https://doi.org/10.1007/s13402-025-01075-4](https://doi.org/10.1007/s13402-025-01075-4)  \nRESEARCH  \nEGFR blockade confers sensitivity to pan-RAS inhibitors in KRASmutated cancers  \nJunling Han1,4 · BoYu3,4 · Jianan Jing2,3,4 · Xiaoyu He3,4 · Yunfen Hua1 · Guotai Xu3,4  \nReceived: 22 January 2025 / Accepted: 16 May 2025 / Published online: 10 July 2025 © The Author(s) 2025  \nAbstract  \nIntroduction KRAS is one of the most commonly occurring mutated oncogene in human cancers. Development of KRAS G12C or G12D inhibitors exhibit promising clinical activities, but patients harboring other hotspot KRAS mutations cannot benefit from those strategies. Recent development in pan-RAS inhibitors have broad therapeutic implications and merit clinical investigation. However, intrinsic and acquired drug resistance caused by tumor heterogeneity greatly limit the clinical application, posing a significant challenge in this field.  \nResults In this study, through CRISPR/Cas9 sgRNA screening using a human kinome sgRNA library, EGFR was discovered to correlate with the sensitivity ofKRAS-mutated tumors to pan-RAS inhibitor RMC-7977 . Through multiple in vitro cell proliferation or viability assays, EGFR loss or pharmacological EGFR inhibition significantly enhances the effectiveness of pan-RAS inhibitors in multiple KRASG12C or KRASG12D cancer cell lines, disregarding their cellular origins. Mechanistically, co-inhibition of EGFR and pan-RAS may further dampen the RTK-RAS-RAF-MEK-ERK pathway activation than either alone, thereby enhancing the anti-tumor activity of pan-RAS inhibitors. Strikingly, with the LL/2 syngeneic mice tumor model, the combination of pan-RAS inhibitors and EGFR inhibitors demonstrated more significant in vivo therapeutic efficacy compared to either single agent.  \nConclusion In conclusion, this study employed high-throughput CRISPR/Cas9 sgRNA screening to identify the enhanced anti-cancer effects when combining EGFR inhibitors with pan-RAS inhibitors in multiple human KRAS-mutated cancer cell lines as well as a mouse syngeneic tumor model. This synergy underscores the potential for a combinational therapy strategy, leveraging EGFR and pan-RAS inhibitors to improve treatment outcomes for patients with KRAS-driven cancers.  \nKeywords Pan-RAS inhibitors · EGFR inhibitors · RTK-RAS-RAF-MEK-ERK pathway · KRAS-mutated cancer · CRISPR/Cas9 sgRNA screening · Combinational therapy  \nJunling Han, Bo Yu and Jianan Jing contributed equally to this work.  \n􀀍 Yunfen Hua [huayf@zjut.edu.cn](huayf@zjut.edu.cn)  \n􀀍 Guotai Xu [xuguotai@nibs.ac.cn](xuguotai@nibs.ac.cn)  \n1 College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China  \n2 College of Life Sciences, Beijing Normal University, Beijing, China  \n3 Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China  \n4 National Institute of Biological Sciences, 7 Science Park Road ZGC Life Science Park, Beijing, China  \n1 Introduction  \nReceptor tyrosine kinases (RTKs) are a family of cell surface receptors, which act as receptors for growth factors, hormones, as well as other extracellular signaling molecules. In the majority of human cancers, RTKs and their downstream signaling cascade mediate key oncogenic signaling pathways that are involved in cell proliferation, differentiation, survival and migration [1, 2]. For example, epidermal growth factor receptor (EGFR) binds to its ligand EGF, resulting in autophosphorylation by its intrinsic tyrosine kinase activity, triggering several oncogenic signal transduction cascades, including RAS-RAFMEK-ERK as well as PI3K-AKT-mTOR signaling pathways [3, 4] . Therefore, constitutive or sustained activation of RTKs or the sequential downstream targets is responsible to tumorigenesis and metastasis in patients. For instance, members  \nof the EGFR family such EGFR or HER2 are often overexpressed or consistently overactivated in certain cancers, which","cbCaieLH9y3GAgeL","https://ap.wps.com/l/cbCaieLH9y3GAgeL","pdf",3866500,"English","# Abstract\n# Introduction\n## RTKs and EGFR signaling\n## EGFR inhibitor generations\n## RAS family and KRAS activation cycle\n# Results\n# Conclusion","[{\"question\":\"What was the key discovery regarding EGFR and pan-RAS inhibitors?\",\"answer\":\"CRISPR/Cas9 sgRNA screening identified EGFR as correlating with sensitivity of KRAS-mutated tumors to the pan-RAS inhibitor RMC-7977.\"},{\"question\":\"How does EGFR inhibition affect pan-RAS inhibitor activity in KRAS-mutated cancers?\",\"answer\":\"EGFR loss or pharmacological EGFR inhibition significantly enhances pan-RAS inhibitor effectiveness across multiple KRAS G12C or G12D cancer cell lines.\"},{\"question\":\"What mechanism and in vivo evidence support the combination strategy?\",\"answer\":\"Co-inhibition of EGFR and pan-RAS further reduces RTK-RAS-RAF-MEK-ERK pathway activation, and the combination shows greater therapeutic efficacy than single agents in a LL/2 syngeneic mouse tumor model.\"}]","EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers - Research Abstract | PDF",1790179223,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/036369a97ef460501fe2420883382afd.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0cbde91a33e23899202745b9eba3f1d.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/236508fb6d077e521137875ae980bd45.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b341260110c80844d1ae74c182821f27.webp",980,1301]